MiR-29 targets Akt3 to reduce proliferation and facilitate differentiation of myoblasts in skeletal muscle development

Cell Death and Disease

Volumn 4, Issue 6, 2013, Pages

  Wei, W ^a   He, H B ^a   Zhang, W Y ^a   Zhang, H X ^a   Bai, J B ^a   Liu, H Z ^a   Cao, J H ^a   Chang, K C ^b   Li, X Y ^a   Zhao, S H ^a  

^a HUAZHONG AGRICULTURAL UNIVERSITY   (China)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Akt3; differentiation; miR 29; myoblast; proliferation

Indexed keywords

AKT3 PROTEIN; CREATINE KINASE MM; MICRORNA 29; MYOGENIN; MYOSIN HEAVY CHAIN; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GROWTH REGULATION; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALE; MOUSE; MUSCLE DEVELOPMENT; MYOBLAST; MYOTUBE; NONHUMAN; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKELETAL MUSCLE; TRANSCRIPTION REGULATION;

EID: 84879667833     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.184     Document Type: Article

References (54)

1. Hutvagner G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme complex. Science 2002; 297: 2056-2060.
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
3. Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev Cell 2006; 11: 441-450.
4. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-355.
5. Yoon AR, Gao R, Kaul Z, Choi IK, Ryu J, Noble JR et al. MicroRNA-296 is enriched in cancer cells and downregulates p21WAF1 mRNA expression via interaction with its 3' untranslated region. Nucleic Acids Res 2011; 39: 8078-8091.
6. Liu K, Liu Y, Mo W, Qiu R, Wang X, Wu JY et al. MiR-124 regulates early neurogenesis in the optic vesicle and forebrain, targeting NeuroD1. Nucleic Acids Res 2010; 39: 2869-2879.
7. Xie SS, Huang TH, Shen Y, Li XY, Zhang XX, Zhu MJ et al. Identification and characterization of microRNAs from porcine skeletal muscle. Anim Genet 2009; 41: 179-190.
8. McDaneld TG, Smith TP, Doumit ME, Miles JR, Coutinho LL, Sonstegard TS et al. MicroRNA transcriptome profiles during swine skeletal muscle development. BMC Genomics 2009; 10: 77.
9. Nakasa T, Ishikawa M, Shi M, Shibuya H, Adachi N, Ochi M. Acceleration of muscle regeneration by local injection of muscle-specific microRNAs in rat skeletal muscle injury model. J Cell Mol Med 2009; 14: 2495-2505.
10. Wang XH, Hu Z, Klein JD, Zhang L, Fang F, Mitch WE. Decreased miR-29 suppresses myogenesis in CKD. J Am Soc Nephrol 2011; 22: 2068-2076.
11. Sylvius N, Bonne G, Straatman K, Reddy T, Gant TW, Shackleton S. MicroRNA expression profiling in patients with lamin A/C-associated muscular dystrophy. FASEB J 2011; 25: 3966-3978.
12. Feng Y, Cao JH, Li XY, Zhao SH. Inhibition of miR-214 expression represses proliferation and differentiation of C2C12 myoblasts. Cell Biochem Funct 2011; 29: 378-383.
13. Kim HK, Lee YS, Sivaprasad U, Malhotra A, Dutta A. Muscle-specific microRNA miR-206 promotes muscle differentiation. J Cell Biol 2006; 174: 677-687.
14. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006; 38: 228-233.
15. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008; 105: 13027-13032.
16. Efanov A, Zanesi N, Nazaryan N, Santanam U, Palamarchuk A, Croce CM et al. CD5\+CD23\+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation. Leukemia 2010; 24: 970-975.
17. Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006; 66: 11590-11593.
18. He A, Zhu L, Gupta N, Chang Y, Fang F. Overexpression of micro ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol 2007; 21: 2785-2794.
19. Kapinas K, Kessler C, Ricks T, Gronowicz G, Delany AM. miR-29 modulates Wnt signaling in human osteoblasts through a positive feedback loop. J Biol Chem 2010; 285: 25221-25231.
20. Li Z, Hassan MQ, Jafferji M, Aqeilan RI, Garzon R, Croce CM et al. Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. J Biol Chem 2009; 284: 15676-15684.
21. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007; 104: 15805-15810.
22. Park SY, Lee JH, Ha M, Nam JW, Kim VN. miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 2009; 16: 23-29.
23. Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010; 51: 836-845.
24. Li L, Sarver AL, Alamgir S, Subramanian S. Downregulation of microRNAs miR-1,-206 and-29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma. Lab Invest 2012; 92: 571-583.
25. Du Y, Gao C, Liu Z, Wang L, Liu B, He F et al. Upregulation of a disintegrin and metalloproteinase with thrombospondin motifs-7 by mir-29 repression mediates vascular smooth muscle calcification. Arterioscler Thromb Vasc Biol 2012; 32: 2580-2588.
26. Huang TH, Zhu MJ, Li XY, Zhao SH. Discovery of porcine microRNAs and profiling from skeletal muscle tissues during development. PLoS One 2008; 3: e3225.
27. Perbellini R, Greco S, Sarra-Ferraris G, Cardani R, Capogrossi MC, Meola G et al. Dysregulation and cellular mislocalization of specific miRNAs in myotonic dystrophy type 1. Neuromuscul Disord 2010; 21: 81-88.
28. Wang L, Zhou L, Jiang P, Lu L, Chen X, Lan H et al. Loss of miR-29 in myoblasts contributes to dystrophic muscle pathogenesis. Mol Ther 2012; 20: 1222-1233.
29. Cacchiarelli D, Martone J, Girardi E, Cesana M, Incitti T, Morlando M et al. MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway. Cell Metab 2010; 12: 341-351.
30. Zhou L, Wang L, Lu L, Jiang P, Sun H, Wang H. A novel target of microRNA-29, Ring1 and YY1-binding protein (Rybp), negatively regulates skeletal myogenesis. J Biol Chem 2012; 287: 25255-25265.
31. Zhou L, Wang L, Lu L, Jiang P, Sun H, Wang H. Inhibition of miR-29 by TGF-beta-Smad3 signaling through dual mechanisms promotes transdifferentiation of mouse myoblasts into myofibroblasts. PLoS One 2012; 7: e33766.
32. Winbanks CE, Wang B, Beyer C, Koh P, White L, Kantharidis P et al. TGF-beta regulates miR-206 and miR-29 to control myogenic differentiation through regulation of HDAC4. J Biol Chem 2011; 286: 13805-13814.
33. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J et al. NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 2008; 14: 369-381.
34. Nakatani K, Thompson DA, Barthel A, Sakaue H, Liu W, Weigel RJ et al. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 1999; 274: 21528-21532.
35. Liby TA, Spyropoulos P, Buff Lindner H, Eldridge J, Beeson C, Hsu T et al. Akt3 controls vascular endothelial growth factor secretion and angiogenesis in ovarian cancer cells, Int J Cancer 2011; 130: 532-543.
36. Cristiano BE, Chan JC, Hannan KM, Lundie NA, Marmy-Conus NJ, Campbell IG et al. A specific role for AKT3 in the genesis of ovarian cancer through modulation of G(2)-M phase transition. Cancer Res 2006; 66: 11718-11725.
37. Madhunapantula SV, Robertson GP. The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res 2009; 22: 400-419.
38. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004; 64: 7002-7010.
39. Sharma A, Sharma AK, Madhunapantula SV, Desai D, Huh SJ, Mosca P et al. Targeting Akt3 signaling in malignant melanoma using isoselenocyanates. Clin Cancer Res 2009; 15: 1674-1685.
40. Liu S, Patel SH, Ginestier C, Ibarra I, Martin-Trevino R, Bai S et al. MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. PLoS Genet 2012; 8: e1002751.
41. Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009; 113: 6669-6680.
42. Fox TE, Houck KL, O'Neill SM, Nagarajan M, Stover TC, Pomianowski PT et al. Ceramide recruits and activates protein kinase C zeta (PKC zeta) within structured membrane microdomains. J Biol Chem 2007; 282: 12450-12457.
43. Sandirasegarane L, Kester M. Enhanced stimulation of Akt-3/protein kinase B-gamma in human aortic smooth muscle cells. Biochem Biophys Res Commun 2001; 283: 158-163.
44. Taniyama Y, Ito M, Sato K, Kuester C, Veit K, Tremp G et al. Akt3 overexpression in the heart results in progression from adaptive to maladaptive hypertrophy. J Mol Cell Cardiol 2005; 38: 375-385.
45. Cardinali B, Castellani L, Fasanaro P, Basso A, Alema S, Martelli F et al. Microrna-221 and microrna-222 modulate differentiation and maturation of skeletal muscle cells. PLoS One 2009; 4: e7607.
46. Wang H, Hertlein E, Bakkar N, Sun H, Acharyya S, Wang J et al. NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Mol Cell Biol 2007; 27: 4374-4387.
47. Mott JL, Kurita S, Cazanave SC, Bronk SF, Werneburg NW, Fernandez-Zapico ME. Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB. J Cell Biochem 2010; 110: 1155-1164.
48. Bakkar N, Wang J, Ladner KJ, Wang H, Dahlman JM, Carathers M et al. IKK/NF-kappaB regulates skeletal myogenesis via a signaling switch to inhibit differentiation and promote mitochondrial biogenesis. J Cell Biol 2008; 180: 787-802.
49. Dogra C, Changotra H, Mohan S, Kumar A. Tumor necrosis factor-like weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor-kappaB and degradation of MyoD protein. J Biol Chem 2006; 281: 10327-10336.
50. Langen RC, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM. Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappaB. FASEB J 2001; 15: 1169-1180.
51. Micheli L, Leonardi L, Conti F, Maresca G, Colazingari S, Mattei E et al. PC4/Tis7/IFRD1 stimulates skeletal muscle regeneration and is involved in myoblast differentiation as a regulator of MyoD and NF-kappaB. J Biol Chem 2010; 286: 5691-5707.
52. Thaloor D, Miller KJ, Gephart J, Mitchell PO, Pavlath GK. Systemic administration of the NF-kappaB inhibitor curcumin stimulates muscle regeneration after traumatic injury. Am J Physiol 1999; 277(2 Pt 1): C320-C329.
53. Malik V, Rodino-Klapac LR, Mendell JR. Emerging drugs for Duchenne muscular dystrophy. Expert Opin Emerg Drugs 2012; 17: 261-277.
54. Mott JL, Kobayashi S, Bronk SF, Gores GJ. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007; 26: 6133-6140.